The Application of Evidence-Based Principles of Care in Older Persons (Issue 6): Urinary Incontinence

Journal of the American Medical Directors Association

Volumn 8, Issue 1, 2007, Pages 35-45

  Zarowitz, Barbara J ^a,b   Ouslander, Joseph G ^c,d  

^a Omnicare Inc   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d and Clinical Care Center (GRECC)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORTALIDONE; DARIFENACIN; DESMOPRESSIN; DOXAZOSIN; DULOXETINE; FLAVOXATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PSEUDOEPHEDRINE; SOLIFENACIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

ACCOMMODATION PARALYSIS; AGED; AMBLYOPIA; ARTICLE; BACKACHE; BEHAVIOR THERAPY; BLOATING; BLURRED VISION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFUSION; CONSTIPATION; COUGHING; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FALLING; GASTROINTESTINAL MOTILITY; GERIATRIC CARE; HALLUCINATION; HEADACHE; HEART; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; INTRAOCULAR PRESSURE; LACRIMATION; LEG PAIN; MEMORY DISORDER; MYDRIASIS; NAUSEA; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; PROSTATE HYPERTROPHY; RESTLESSNESS; SIDE EFFECT; STRESS INCONTINENCE; SUSTAINED RELEASE FORMULATION; SWEATING; TACHYCARDIA; URGE INCONTINENCE; URINARY HESITANCY; URINE INCONTINENCE; URINE RETENTION; VISION; VISUAL DISORDER; VOMITING; XEROSTOMIA;

EID: 33845940772     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.09.011     Document Type: Article

References (82)

1. Harrington C., Carrillo H., and Mercado-Scott C. Nursing facilities, staffing, residents, and facility deficiencies, 1998 through 2004. Urinary Incontinence and Bladder Training (2005), Agency for Health Care Policy and Research, US Department of Health and Human Services, Rockville, MD 52-53 AHCPR Publication H500-97-0002
2. Durrant J., and Snape J. Urinary incontinence in nursing homes for older people. Age Ageing 32 (2003) 12-18
3. Nelson R., Furner S., and Jesudason V. Urinary incontinence in Wisconsin skilled nursing facilities: Prevalence and associations in common with fecal incontinence. J Aging Health 13 (2001) 539-547
4. McDonagh MS, Selover D, Santa J, Lopez S. Drug class review on agents for overactive bladder. Final Report. December 2005. Oregon Health & Science University, copyright 2005. Available at: http://www.ohsu.edu/drugeffectiveness/reports/final.cfm. Accessed June 8, 2006.
5. Fonda D., DuBeau C., Palmer M.H., et al. Incontinence in the frail elderly. In: Abrams P., Cardozo L., Khoury S., et al. (Eds). Incontinence Vol. 2 (2005), Health Publications Limited, Editions 21, Paris France, 1165-1239
6. Creason N.S., Grybowski J.A., Burgener S., et al. Prompted voiding therapy for urinary incontinence in aged female nursing home residents. J Adv Nurs 14 (1989) 120-126
7. Schnelle J.F. Treatment of urinary incontinence in nursing home patients by prompted voiding. J Am Geriatr Soc 38 (1990) 356-360
8. Burgio L.D., McCormick L.A., Schreve A.S., et al. The effects of changing prompted voiding schedules in the treatment of incontinence in nursing home residents. J Am Geriatr Soc 42 (1994) 315-320
9. Ouslander J.G., and Schnelle J.F. Incontinence in the nursing home. Ann Intern Med 122 (1995) 4348-4349
10. Ouslander J.G., Griffiths P., McConnell E., et al. Functional incidental training: Applicability and reliability in the Veterans Affairs nursing home patient population. J Am Med Dir Assoc 6 (2005) 121-127
11. National Nursing Home Quality Measures. User's Manual. US Department of Health and Human Services, Centers for Medicare and Medicaid Serivces. November 2004 (v1.2). Available at: http://www.cms.hhs.gov/NursingHomeQualityInits/. Accessed September 9, 2006.
12. Schnelle J.F., and Ouslander J.G. CMS guidelines and improving continence care in nursing homes: the role of the medical director. J Am Med Dir Assoc 7 (2006) 131-132
13. Ouslander J.G., Osterweil D., and Morley J. Incontinence. In: Ouslander J.G., Osterweil D., and Morley J. (Eds). Medical Care in the Nursing Home. 2nd ed. (1996), McGraw-Hill Professional, New York 225-249
14. Jumadilova Z., Zyczynski P., Paul B., and Narayanan S. Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment. Am J Manag Care 11 (2005) S112-S120
15. Agency for Health Care Policy and Research. Clinical Practice Guidelines. Urinary Incontinence in Adults: Acute and Chronic Management (1996), Department of Health and Human Services, Rockville, MD AHCPR publication 96-0682
16. Ouslander J.G. Management of overactive bladder. N Engl J Med 350 (2004) 786-799
17. Resnick N.M., Yalla S.V., and Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 320 (1989) 1-7
18. American Medical Directors Association. Clinical Practice Guideline: Urinary Incontinence. Available at: http://www.amda.com/tools/cpg/incontinence.cfm. Accessed September 9, 2006.
19. State Operations Manual: Surveyor Guidance for Urinary Incontinence and Catheters. Centers for Medicare and Medicaid Services, Department of Health and Human Services. F315 42CFR 483. 25(d) (1) and (2) urinary incontinence and catheters. April 2005.
20. Schmidt R.A., Zermann D.H., and Doggweiler R. Urinary incontinence update: Old traditions and new concepts. Adv Intern Med 44 (1999) 19-57
21. Burgio K.L., Locher J.L., Goode P.S., et al. Behavioral and drug treatment for urge incontinence in older women: A randomized controlled trial. JAMA 280 (1998) 1995-2000
22. Burgio K.L., Locher J.L., and Goode P.S. Combination behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 48 (2000) 370-374
23. Mattiasson A., Blaakaer J., Hove K., and Wein A.J. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 91 (2003) 54-60
24. Shubak L.L., Quesenberry C.P., Posner S.F., et al. The effect of behavioral therapy on urinary incontinence: A randomized, controlled trial 100 (2002) 72-78
25. Goode P.S., and Burgio K.L. Pharmacologic treatment of lower urinary tract dysfunction in geriatric patients. Am J Med Sci 314 (1997) 262-267
26. Yoshimura N., and Chancellor M.B. Current and future pharmacological treatment for overactive bladder. J Urol 168 (2002) 1897-1913
27. Schwinn D.A. Novel role for alpha-1 adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 86 suppl 2 (2000) 11-20
28. Norton P.A., Zinner N.R., Yalcin I., and Bump R.C. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187 (2002) 40-48
29. McCormack P.L., and Keating G.M. Duloxetine: In stress urinary incontinence. Drugs 64 22 (2004) 2567-2573
30. Debruyne F.M., Witjes W.P., Fitzpatrick J., Kirby R., Kirk D., and Prezioso D. The international terazosin trial: A multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol 30 (1996) 369-376 [Erratum: Eur Urol 1997;31:458.]
31. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazoin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335 (1996) 533-539
32. Lepor H., Kaplan S.A., Klimberg I., et al. Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. J Urol 157 (1997) 525-530
33. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urol 51 (1998) 892-900
34. Lepor H., Williford W.O., Barry M.J., et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 160; (1998) 1358-1367
35. Roehrborn C.G., Van Kerrebroeck P., and Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92 (2003) 257-261
36. Boyle P., Robertson C., Manski R., Padley R.J., and Roehrborn C.G. Meta-analysis of randomized trials of terozosin the treatment of benign prostatic hyperplasia. Urol 58 (2001) 717-722
37. Lee K.S., Choo M.S., Kim D.Y., et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: A prospective, randomized, controlled multicenter study. J Urol 174 (2005) 1334-1338
38. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
39. Langer S.Z. History and nomenclature of alpha-1 adrenoreceptors. Eur Urol 36 Suppl1 (1999) 2-6
40. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The antihypertensive and lipid lowering treatment to prevent attack trial (ALLHAT). JAMA 283 (2000) 1967-1975
41. Carruthers S.G. Adverse effects of alpha 1-adrenergic blocking drugs. Drug Safety 11 (1994) 12-20
42. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the third US Preventive Services Task Force. Am J Prev Med 20 (2001) 21-35
43. Anonymous. Undertaking systematic review of research on effectiveness: CRDs guidance for those carrying out or commissioning reviews. 2nd ed (2001), NHS Centre for Reviews and Dissemination, York, UK CRD Report Number 4
44. Abrams P., Freeman R., Anderstrom C., and Mattiasson A. Tolterodine, a new amtimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81 (1998) 801-810
45. Lee J.G., Hong J.Y., Choo M.S., et al. Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 9 (2002) 247-252
46. Malone-Lee J., Shaffu B., Anand C., and Powell C. Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial. J Urol 165 (2001) 1452-1456
47. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., and Wein A. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of overactive bladder. Urol 57 (2001) 414-421
48. Ouslander J.G., Maloney C., Grasela T.H., et al. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc 2 (2001) 207-214
49. Birns J., Lukkari E., Malone-Lee J.G., et al. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 85 (2000) 793-798
50. Zinner N.R., Mattiasson A., and Stanton S.L. Efficacy, safety and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 50 (2002) 799-807
51. Diokno A.C., Appell R.A., Sand P.K., et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolerodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 78 (2003) 687-695
52. Drutz H.P., Appell R.A., Gleason D., et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Flood Dysfunct 20 (1999) 283-289
53. Halaska M., Ralph G., Wiedemann A., et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20 (2003) 392-399
54. Chapple C.R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended-release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 48 (2005) 464-470
55. Ouslander J.G., Schnelle J.F., Uman G., et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 43 (1995) 610-617
56. Wagg A., Wyndaele J.J., and Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother 4 (2006) 14-24
57. Versi E., Appell R., Mobley D., et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 95 (2000) 718-721
58. Anderson R.U., Mobley D., Blank B., et al. Once daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 161 (1999) 1809-1812
59. Homma Y., Paick J.S., Lee J.G., et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: A randomized, placebo-controlled trial. BJU Int 92 (2003) 741-747
60. Barkin J., Corcos J., Radomski S., et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge incontinence. Clin Ther 26 (2004) 1026-1036
61. Chapple R.C., Rechberger T., Al-Shukri S., et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93 (2004) 303-310
62. Lawrence M., Guay D.R., Benson S.R., and Anderson M.J. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: A population analysis. Pharmacother 20 (2000) 470-475
63. Chu F.M., Dmochowski R.R., Lama D.J., et al. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: A subanalysis of data from the OPERA trial. Am J Obstet Gynecol 192 (2005) 1849-1854
64. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
65. In: McEvoy G.K., Litvak K., Welsh O.H., et al. (Eds). AHFS Drug Information 2004 (2004), American Society of Health-System Pharmacists, Bethesda, MD
66. Katz I.R., Sands L.P., Bilker W., et al. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc 46 (1998) 8-13
67. Tsao J.W., and Heilman K.M. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 349 (2003) 2274-2275
68. Williams S.G., and Staudenmeier J. Hallucinations with tolterodine. Psychiatr Serv 55 (2004) 1318-1319
69. van der Velde N., Ziere G., and van der Cammen T.J. Falls in three patients due to timolol eye drops, tolterodine, and flecainide. J Gerontol A Biol Sci Med Sci 59 (2004) 1343-1344
70. Womack K.B., and Heilman K.M. Tolterodine and memory: Drug but forgetful. Arch Neurol 60 (2003) 771-773
71. Donellan C.A., Fook L., McDonald P., and Playfer J.R. Oxybutynin and cognitive dysfunction. Br Med J 315 (1997) 1363-1364
72. Shader R.I., and Oesterheld J.R. Case 7: The addled nonagenerian. J Clin Psychopharmacol 15 (1995) 378
73. Kay G., Crook T., Rekeda L., et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50 (2006) 317-326
74. Lipton R.B., Dolodner K., and Wesnes K. Assessment of cognitive function of the elderly population: Effects of darifenacin. J Urol 173 (2005) 493-498
75. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 163 (2003) 2716-2724
76. Urinary Incontinence: Anticholinergic Agents, Genitourinary Smooth Muscle Relaxants. Geriatric Pharmaceutical Care Guidelines (2006), Omnicare, Inc, Covington, KY 673-688
77. Lose G., Mattiasson A., Walter S., et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 172 (2004) 1021-1025
78. Lose G., Lalos O., Freeman R.M., et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: A double-blind placebo-controlled study in women. Obstet Gyn 189 (2003) 1106-1113
79. Mattiasson A., Abrams P., Van Kerrebroeck P., et al. Efficacy of desmopressin in the treatment of nocturia: A double-blind, placebo-controlled study in men. BJU Int 89 (2002) 855-862
80. Rembratt A., Riis A., and Morgaard J.P. Desmopressin treatment in nocturia: An analysis of risk factors for hyponatremia. Neurourol Urodyn 25 (2006) 105-109
81. Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: A systematic review and meta-analysis. Neurourol Urodyn 23 (2004) 302-305
82. Engberg S., Kincade J., and Thompson D. Future directions for incontinence research with frail elders. Nursing Res 53; (2004) S22-S29